These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 38263792)

  • 1. Different minimal alcohol consumption in male and female individuals with metabolic dysfunction-associated fatty liver disease.
    Zhu Y; Xu X; Fan Z; Ma X; Rui F; Ni W; Hu X; Gu Q; Shi J; Wu C; Yeo YH; Li J
    Liver Int; 2024 Mar; 44(3):865-875. PubMed ID: 38263792
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolic dysfunction-associated fatty liver disease and excessive alcohol consumption are both independent risk factors for mortality.
    van Kleef LA; de Knegt RJ; Brouwer WP
    Hepatology; 2023 Mar; 77(3):942-948. PubMed ID: 35776631
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of Alcohol Consumption and Metabolic Syndrome on Mortality in Patients With Nonalcoholic and Alcohol-Related Fatty Liver Disease.
    Younossi ZM; Stepanova M; Ong J; Yilmaz Y; Duseja A; Eguchi Y; El Kassas M; Castellanos-Fernandez M; George J; Jacobson IM; Bugianesi E; Wong VW; Arrese M; de Ledinghen V; Romero-Gomez M; Mendez-Sanchez N; Ahmed A; Wong R; Papatheodoridis G; Serfaty L; Younossi I; Nader F; Ziayee M; Afendy A;
    Clin Gastroenterol Hepatol; 2019 Jul; 17(8):1625-1633.e1. PubMed ID: 30476585
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Associations between Healthy Lifestyle and All-Cause Mortality in Individuals with Metabolic Associated Fatty Liver Disease.
    Wang X; Wang A; Zhang R; Cheng S; Pang Y
    Nutrients; 2022 Oct; 14(20):. PubMed ID: 36296904
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolic dysfunction-associated fatty liver disease and heavy alcohol consumption increase mortality:A nationwide study.
    Cho SH; Kim S; Oh R; Kim JY; Lee YB; Jin SM; Hur KY; Kim G; Kim JH
    Hepatol Int; 2024 May; ():. PubMed ID: 38806774
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ethyl glucuronide in hair detects a high rate of harmful alcohol consumption in presumed non-alcoholic fatty liver disease.
    Staufer K; Huber-Schönauer U; Strebinger G; Pimingstorfer P; Suesse S; Scherzer TM; Paulweber B; Ferenci P; Stimpfl T; Yegles M; Datz C; Trauner M
    J Hepatol; 2022 Oct; 77(4):918-930. PubMed ID: 35605744
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic Dysfunction-associated Fatty Liver Disease and Mortality Among Chinese Adults: a Prospective Cohort Study.
    Wang X; Wu S; Yuan X; Chen S; Fu Q; Sun Y; Lan Y; Hu S; Wang Y; Lu Y; Qu S; Wang L
    J Clin Endocrinol Metab; 2022 Jan; 107(2):e745-e755. PubMed ID: 34467980
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of metabolic phenotype and alcohol consumption on mortality risk in metabolic dysfunction-associated fatty liver disease: a population-based cohort study.
    Charatcharoenwitthaya P; Karaketklang K; Aekplakorn W
    Sci Rep; 2024 Jun; 14(1):12663. PubMed ID: 38830939
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A new risk stratification strategy for fatty liver disease by incorporating MAFLD and fibrosis score in a large US population.
    Zhang YC; Lyu ZY; Ma B; Li LM; Wang W; Sheng C; Dai HJ; Huang YB; Song FF; Song FJ; Chen KX
    Hepatol Int; 2022 Aug; 16(4):835-845. PubMed ID: 35701716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolic dysfunction-associated fatty liver disease is associated with increased all-cause mortality in the United States.
    Kim D; Konyn P; Sandhu KK; Dennis BB; Cheung AC; Ahmed A
    J Hepatol; 2021 Dec; 75(6):1284-1291. PubMed ID: 34380057
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association between serum uric acid levels and long-term mortality of metabolic dysfunction-associated fatty liver disease: a nationwide cohort study.
    Liu Z; Wang Q; Huang H; Wang X; Xu C
    Diabetol Metab Syndr; 2023 Feb; 15(1):27. PubMed ID: 36814289
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of alcohol on newly developed metabolic dysfunction-associated fatty liver disease in both sexes: A longitudinal study.
    Sogabe M; Okahisa T; Kagawa M; Ueda H; Kagemoto K; Tanaka H; Kida Y; Tomonari T; Taniguchi T; Okamoto K; Miyamoto H; Sato Y; Nakasono M; Takayama T
    Clin Nutr; 2023 May; 42(5):810-816. PubMed ID: 37043935
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association between carotenoid intake and metabolic dysfunction-associated fatty liver disease among US adults: A cross-sectional study.
    Zhang H; Li L; Jia L; Liu J
    Medicine (Baltimore); 2023 Dec; 102(51):e36658. PubMed ID: 38134087
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the role of alcohol consumption and qualitative abdominal fat on NAFLD and MAFLD in males and females.
    Sogabe M; Okahisa T; Kurihara T; Kagawa M; Ueda H; Kawaguchi T; Fukuya A; Kagemoto K; Tanaka H; Kida Y; Tomonari T; Taniguchi T; Okamoto K; Miyamoto H; Sato Y; Nakasono M; Takayama T
    Sci Rep; 2022 Sep; 12(1):16048. PubMed ID: 36163355
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between serum 25-hydroxy vitamin D concentrations and mortality among individuals with metabolic dysfunction-associated fatty liver disease: a prospective cohort study.
    Zhang JJ; Yu HC; Li Y; Zhang YB; Geng TT; Lu Q; Liao YF; Guo KQ; Du L; Ruan HL; Yang K; Liu G; Pan A
    Am J Clin Nutr; 2022 Nov; 116(5):1409-1417. PubMed ID: 36107812
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence, characteristics, and mortality outcomes of obese and nonobese MAFLD in the United States.
    Dao AD; Nguyen VH; Ito T; Cheung R; Nguyen MH
    Hepatol Int; 2023 Feb; 17(1):225-236. PubMed ID: 36309601
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MAFLD and risk of CKD.
    Sun DQ; Jin Y; Wang TY; Zheng KI; Rios RS; Zhang HY; Targher G; Byrne CD; Yuan WJ; Zheng MH
    Metabolism; 2021 Feb; 115():154433. PubMed ID: 33212070
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trends in prevalence and all-cause mortality of metabolic dysfunction-associated fatty liver disease among adults in the past three decades: Results from the NHANES study.
    Xie ZQ; Li HX; Wang BK; Yang ZM; Zhang ZY; Tan WL; Li WX; Wang QB; Yang L; Zhuang HK; Tang CW; Shang CZ; Chen YJ
    Eur J Intern Med; 2023 Apr; 110():62-70. PubMed ID: 36754655
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of the Metabolic Dysfunction-Associated Fatty Liver Disease with Serum Uric Acid-to-Creatinine Ratio.
    Han AL; Lee HK
    Metab Syndr Relat Disord; 2022 Sep; 20(7):370-376. PubMed ID: 35796698
    [No Abstract]   [Full Text] [Related]  

  • 20. Comparison of MAFLD and NAFLD diagnostic criteria in real world.
    Lin S; Huang J; Wang M; Kumar R; Liu Y; Liu S; Wu Y; Wang X; Zhu Y
    Liver Int; 2020 Sep; 40(9):2082-2089. PubMed ID: 32478487
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.